Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYP001a plus nucleos(t)ide analogues in virologically suppressed chronic hepatitis B
2019-001629-28Phase 2Active
- Sponsor
- ENYO Pharma
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing EYP001a + nucleos(t)ide analogues with Placebo + nucleos(t)ide analogues (2 arms). Primary endpoint: HBsAg decline from baseline to Week 16. Started Jul 2019; status: active.
02
Drugs
vonafexor
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2019-001629-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001629-28.